**DARE CAB Criteria and Options for Extended ATIs**

**Main Inclusion Criteria**

• Male or female, age 18+ with no maximum age criteria if people are otherwise healthy and fall within the Inclusion/Exclusion Criteria

• Screening CD4+ T-cell count = >500 cells/mm3

• Nadir = >350 cells/mm3

**Main Exclusion Criteria**

• Any history of an HIV-associated malignancy, including Kaposi’s sarcoma and any type of lymphoma, or virus-associated cancers, including cervical and anal cancer

• Active or recent non-HIV-associated malignancy requiring systemic chemotherapy or surgery in the preceding 36 months

• History of or current active hepatitis B (HBV) infection defined as positive HBV surface antigen test

• Active hepatitis C (HCV) infection
  
  • Severe Liver Disease
  
  • Severe Renal Disease

• Active and poorly controlled atherosclerotic cardiovascular disease

• Atherosclerotic cardiovascular disease risk by history confirmed by EKGs and stress test
  
  • History of AIDS defining illnesses occurring less than 10 years ago

• History of neurologic disease, including dementia, PML and strokes

• History of potential immune-mediated medical conditions

**ART Restart Criteria Options**

• Confirmed CD4 count decline to below 350 cells/mm3

• Acute retroviral syndrome

• Sustained or high–level viremia

• 1) viremia > 50,000 copies RNA/mL for four weeks,

• 2) viremia > 10,000 copies RNA/mL 6 weeks,

• 3) viremia > 2000 copies RNA/ml for 12 weeks or

• 4) viremia > 400 copies/RNA for 24 weeks
**Engagement Options for Partners of Participants**

- HIV testing, PrEP and PEP referral information and counseling provided to participants at the study site
- HIV testing, PrEP and PEP referral information and counseling provided to participants and their partners at the study site
- HIV testing, PrEP and PEP referral information and counseling provided to participants and their partners at the study site and no cost PREP provided to partners by the study site

**Viral Load Monitoring Options During ATIs**

- Weekly monitoring during weeks 8-12
- Biweekly monitoring thereafter in the absence of viral rebound
- Home testing?